Bk1803

Phase 3

Tanabe Pharma Corporation

Bk1803 is one of 2 therapeutic programs targeting Pertussis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

PertussisNot yet recruiting

PertussisPhase 3

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Pertussis

#DrugCompanyPhaseTrials

Bk1803

Tanabe Pharma Corporation

Phase 3

1 2

Bordetella Pertussis B1917

UUniversity of Southampton

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 3Not yet recruiting

Pertussis

NCT07793513

Clinical

Trials by Indication[1]

Pertussis1 trial

Confirmatory Study of BK1803 in Healthy Infants (Comparative Study Using GOBIK Aqueous Suspension Syringes and Bimmugen® Injection as a Control)

Not yet recruiting· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 3·NCT07793513·344 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bk1803. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Bk1803. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Tanabe Pharma Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Tanabe Pharma Corporation

Bk1803

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Pertussis1 trial

References

Drug Info

Quick Facts

Related News